Teladoc Health vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
$2.56B revenue 2024; Q2 2025 $631.9M (-1.6% YoY); 101-103M projected US members 2025; telehealth market leader; telehealth market $123.26B 2024 to $455.27B 2030; 46.58% North America share
About
Teladoc Health is the world's largest telehealth company, founded in 2002 and headquartered in Purchase, New York, that pioneered on-demand virtual healthcare delivery in the United States. The company was founded on the premise that patients should be able to access physicians anytime and anywhere without traveling to a physical office — a model that took over a decade to gain mainstream acceptance before becoming a necessity during the COVID-19 pandemic. Teladoc's mission is to provide whole-person virtual care that addresses physical health, mental health, and chronic condition management through an integrated digital platform.\n\nTeladoc's platform encompasses general medical, dermatology, nutrition, and specialty care through its core telehealth offering; mental health and therapy through BetterHelp, the world's largest online therapy platform; virtual primary care and chronic condition management through Teladoc Primary360; and complex care navigation through its integrated whole-person health approach. The company serves employers, health plans, hospitals, and health systems, delivering virtual care to members across the US and internationally. BetterHelp has become a significant consumer-facing revenue driver, connecting individuals directly with licensed therapists without employer or insurance intermediaries.\n\nTeladoc reported $2.56 billion in revenue for 2024 and projects 101 to 103 million US members in 2025. The company trades on the NYSE under TDOC and holds a substantial lead in telehealth market share through its scale, multi-specialty breadth, and direct-to-consumer mental health reach via BetterHelp. Despite post-pandemic normalization and the $13.7 billion Livongo write-down in 2022, Teladoc remains the largest and most diversified virtual care platform, with continued investment in AI-powered clinical decision support and chronic disease management to drive the next phase of growth.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.